Journal of Drug Metabolism & Toxicology
Open Access

Metallo-beta-lactamase producing Acinetobacter spp from clinical isolates at a tertiary care hospital in Accra, Ghana

Joint Event on 31^st Euro Global Summit and Expo on Vaccines & Vaccination & 4^th World Congress and Exhibition on Antibiotics and Antibiotic Resistance

June 14-16, 2018 Barcelona, Spain

Michael Adetokunbo Olu-Taiwo

University of Ghana, Ghana

Posters & Accepted Abstracts: J Drug Metab Toxicol

Abstract :

One of the most pertinent issues in health-care institutions is the emergence and global spread of metallo-�?²-lactamase (MBL) producing bacteria of blaVIM-, blaIMP- and blaNDM-types. MBL-producing-Acinetobacter has become a public health concern due to therapeutic treatment challenges associated with nosocomial infections. In Ghana, limited information is available on clinical isolates of MBL-producing-Acinetobacter The aim of the study was to determine the prevalence of MBL-producingAcinetobacter species in clinical isolates from the Korle-Bu Teaching Hospital, Accra. A total of 87 archived clinical isolates of Acinetobacter were collected from cultures of aspirates, urine, ear, eye and wound swabs. Susceptibility pattern was done by Kirby-Bauer disk diffusion method. Meropenem-resistant Acinetobacter isolates were screened for enzymes using modified Hodge test (MHT) and IPM+IPM-EDTA combined disc test (CDT). Additionally, multiplex PCR was used to determined MBL genes (blaVIM-1, blaIMP-1 and blaNDM-1) in MBL-producing Acinetobacter isolates. Acinetobacter isolates showed high levels of antibiotic resistant to ampicillin (94.2%), amoxicillin-clavulanate (90.8%), amikacin (25.3%), cefotaxime (90.8%), cefuroxime (86.2%), ceftadizime (75.9%), co-trimoxazole (70.1%), ciprofloxacin (64.4%), gentamicin (72.4%), nitrofurantoin (92%) and levofloxacin (67.8%). A total of 84 (96.7%) of Acinetobacter isolates were multidrug-resistant. Out of 52 (59.8%) meropenem-resistant Acinetobacter, 3 (5.8%) were carbapenemase producers by MHT whilst, 23 (44.2%) were MBL producers by CDT. There was no statistical significance difference between the antimicrobial resistant pattern of MBL-producing and NonMBL-producing (p-value >0.05). A total of 7 out of 23 (30.4%) MBL-producing-Acinetobcter harboured blaNDM-1. Of these, 4 (57.1%) were from wound swabs, urine 2 (28.6%) and ear swab 1 (14.3%) However, no blaVIM-1 or blaIMP-1 was detected. In conclusion, MBL-producing-Acinetobacter isolates showed a high level of resistance to multiple antimicrobials. The detection of blaNDM-1 amongst MBL-producing-Acinetobacter is a cause for concern and strict antibiotics usage and infection control measures should be instituted to prevent the spread of these resistance genes in our health-care institutions. michaelolutaiwo@gmail.com